Related Experiment Videos
Low-Dose Chidamide Maintenance Therapy After Hematopoietic Stem Cell Transplantation for T-Cell Acute Lymphoblastic
Shen-Hao Liu1,2, Ai-Ni Deng1,2, Hui-Ying Li1,2
1National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Abstract:
Post-transplant relapse remains a major challenge in T-ALL, with limited effective salvage options. We report on eight T-ALL patients who received low-dose chidamide (5 mg once weekly) as maintenance therapy after allogeneic HSCT. With a median follow-up of 22.7 months, the estimated 2-year OS and EFS are both 87.5%. Seven patients (87.5%) remain in continuous complete remission with sustained MRD negativity. Grade 3-4 neutropenia occurred in 57.1% of evaluable patients but was clinically manageable. This case series demonstrates that a low-dose chidamide maintenance regimen is feasible, well tolerated, and promising in this setting.
